Patent claims

B1

1. Human G-protein coupled receptor EDG6 with the sequence 1 as well as its fragments, variants and mutations.

2. Murine G-protein coupled receptor EDG6 with the sequence 4 as well as its fragments, variants and mutations.

3. DNA sequence coding the human G-protein coupled receptor EDG6 as well as its fragments, variants and mutations.

4. DNA according to claim 3, wherein there exists sequence 2.

5. DNA sequence coding the murine G-protein coupled receptor EDG6 as well as its fragments, variants and mutations.

6. DNA according to claim 5, wherein there exists sequence 3.

7. Vectors containing a DNA sequence, if applicable coupled to a suitable promoter in accordance with claims 3~~-6~~.

8. Host cells containing vectors according to claim 7.

9. Antibodies against human or murine EDG6 G-protein coupled receptors.

10. Monoclonal antibodies according to claim 9.

09786926.050401

11. Test kit for detection of the EDG6 receptor on the basis of monoclonal antibodies according to claim 10.

12. Test kit for detection of the EDG6 receptor on the basis of nuclein acid diagnostics.

13. Use of the EDG6 receptor as well as its fragments, variants and mutations and, if applicable, its binding partners for therapeutic methods and treatments.

14. Use according to claim 13, wherein the therapeutic methods influence the function of blood and body cells, for example leading to the inhibition of chronic and acute inflammations.

09758925.050401

15. Use of the EDG6 receptor as well as its fragments, variants and mutations and, if applicable, its binding partners according to claims ~~13 — 14,~~ 15 wherein there exists the use for gene-therapeutic methods and treatments.

16. Use of the monoclonal antibodies according to claim 10, if applicable coupled to other molecules and substances, for example therapeutic agents, toxins or antibodies, for therapeutic methods and treatments.

17. Use according to claim 16, wherein the therapeutic measures influence the function of the EDG6 receptor, for example in immune and inflammatory reactions.

18. EDG6-deficient mouse strains containing function-free mutants ('zero mutants') of the EDG6.

19. Mouse strains according to claim 18, into which further gene deficiencies have been crossed, for example for immuno-modulatory and immuno-regulatory gene functions, such as receptors or signal molecules.

a

20. Use of mice according to claims 18~~-19~~ as animal models for diseases connected ~~with~~ receptor EDG6.

add B2

09786926.050401